Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07197541

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts

All patients were treated as self-control. Half of the warts received bleomycin injection and the other half received pingyangmycin injection for 24 weeks. During the treatment period, before each injection, photos of the skin lesions must be taken, the diameter of the skin lesions must be measured, the DLQI(Dermatology Life Quality Index) and NRS scores(NRS scores) must be filled in, and adverse events must be recorded. Before the first treatment, HPV(Human Papilloma virus) virus typing is performed on the warts.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Plantar Wart

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

The second Affiliated hospital of Zhejiang university school of medicine

Hangzhou, Zhejiang, 310009, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged over 18 years old;
  • Clinical diagnosis of plantar warts;
  • The diameter of a single wart is ≥1cm, and the number is ≥2;
  • There is a history of other treatments for plantar warts within 4 weeks, including drugs and physical therapy;
  • Have a basic understanding of the purpose, effects and possible adverse reactions of the trial, and sign an informed consent form in accordance with the spirit of the Declaration of Helsinki.

Exclusion criteria

  • There are other local infections in the treatment area and injection is not suitable;
  • Patients allergic to lidocaine, bleomycin, and pingyangmycin;
  • Patients with other serious skin diseases, tumors or other systemic diseases;
  • Patients with infections such as tuberculosis, HIV, hepatitis B, hepatitis C;
  • Patients with a history of other treatments for plantar warts in the previous 4 weeks, including drugs and physical therapy;
  • Patients who have participated in other clinical trials in the past 3 months;
  • Pregnant women, lactating women, or patients who plan to become pregnant during the trial;
  • Those who have any history of major surgery in the previous 8 weeks or who may have surgery planned during treatment;
  • Patients with a history of mental illness.

Treatment and study plan

Hyperthermia Therapy

Device

Device-mediated constant-temperature hyperthermia at approximately 44°C.

Pingyangmycin Injection

Drug

Pingyangmycin injection treatment group: local injection treatment, once every 4 weeks.

Bleomycin Injection

Drug

Bleomycin injection treatment group: local injection treatment, once every 4 weeks.

Primary outcomes

  1. Skin lesions completely cleared

    Time frame: Week 24

    The patient's plantar wart lesions were completely cleared

Secondary outcomes

  1. Follow up to 36 weeks with no recurrence

    Time frame: Week 52

    There was no recurrence of plantar warts in the patient at 36 weeks of follow-up.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 29, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.